New York, Jan 14, 2026, 14:09 EST — Regular session
- Nuvalent shares climbed roughly 6% during afternoon trading
- The company recently set 2026 targets for its leading lung cancer drug
- The filing revealed roughly $1.4 billion in cash at year-end, with a runway expected to extend into 2029
Nuvalent’s stock climbed roughly 6% Wednesday afternoon, building on earlier gains as the biotech detailed crucial 2026 goals for its lead lung-cancer project and highlighted a sizable cash pile expected at year-end.
This matters since Nuvalent remains a clinical-stage company. Investors want a clearer timeline for its first possible U.S. product launch and some indication it won’t need to raise capital again anytime soon.
Nuvalent’s update sets a firm deadline for the next major catalyst: the U.S. Food and Drug Administration’s decision timeline on its first potential approval, a move that could quickly shift early-stage biotech expectations.
Nuvalent (ticker: NUVL) climbed $5.84, or 5.8%, to reach $107.01 around 2:09 p.m. EST. Earlier, it hit a high of $108.24 and dipped as low as $99.93 during the session.
On Monday, the Cambridge, Massachusetts-based company announced the FDA had accepted its new drug application (NDA) for zidesamtinib. The filing targets approval for patients with ROS1-positive non-small cell lung cancer. The agency set a PDUFA action date of Sept. 18, 2026, under the user-fee law that governs FDA review timelines.
Nuvalent laid out its 2026 targets, including a planned U.S. commercial launch for zidesamtinib—if it secures approval—and an NDA submission for neladalkib slated for the first half of 2026, targeting ALK-positive non-small cell lung cancer.
“Over the past two years, the Nuvalent team has delivered steadily on our OnTarget 2026 operating plan,” CEO James Porter said in the statement. CFO Alexandra Balcom added that the company’s “strong financial position allows us to zero in on the execution of a first U.S. launch” while moving the pipeline forward. Nuvalent Investors
A regulatory filing tied to this update revealed Nuvalent’s preliminary cash, cash equivalents, and marketable securities estimate at roughly $1.4 billion as of Dec. 31, 2025. The company noted this number is unaudited and might shift following year-end closing procedures.
The path remains binary. The FDA might extend review timelines, demand additional data, or reject the application altogether. Any delay would probably push back launch plans and force Nuvalent to keep burning cash for a longer stretch.
Investors now focus on any fresh updates from the FDA’s review of zidesamtinib as the Sept. 18, 2026 deadline approaches. They’ll also be watching to see if Nuvalent follows through on its plan to file an NDA for neladalkib in the first half of 2026.
